Syncona launches Treg company Quell with £35 million A round

Syncona hopes newly launched Treg cell company Quell Therapeutics can generate clinical data on at least one program within the lifespan of its £35 million ($44.6 million) series A round, announced Monday. The start-up is setting its sights on autoimmune, inflammatory and transplant-related diseases.

The firm supplied all but £1 million ($1.3 million) of the round, with UCL Technology Fund providing the balance...